MAP2K1 and melanoma: Among MAPKKs (MAP2Ks), somatic mutations have been reported mainly for MEK1 whose overall mutational prevalence in malignant melanomas is 6–7% [84]; the prevalence of these mutations in different melanoma subtypes and anatomical regions is currently unknown.